The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

Marianne G. Pouwer; Elsbet J. Pieterman; Lars Verschuren; Martien P. M. Caspers; Cornelis Kluft; Ricardo A. Garcia; Jurjan Aman; J. Wouter Jukema; Hans M. G. Princen

doi:10.3389/fcvm.2018.00055

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

Marianne G. Pouwer, Elsbet J. Pieterman, Lars Verschuren, Martien P. M. Caspers, Cornelis Kluft, Ricardo A. Garcia, Jurjan Aman, J. Wouter Jukema, Hans M. G. Princen

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Article number	55
Journal	Frontiers in cardiovascular medicine
Volume	5
DOIs	https://doi.org/10.3389/fcvm.2018.00055
Publication status	Published - 12 Jun 2018

Access to Document

10.3389/fcvm.2018.00055

Cite this

Pouwer, M. G., Pieterman, E. J., Verschuren, L., Caspers, M. P. M., Kluft, C., Garcia, R. A., Aman, J., Jukema, J. W., & Princen, H. M. G. (2018). The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model. Frontiers in cardiovascular medicine, 5, [55]. https://doi.org/10.3389/fcvm.2018.00055

@article{af05d3798d69427e99b1614aca7bdab3,

title = "The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model",

keywords = "atherosclerosis, animal model cardiovascular disease, lipids and lipoprotein metabolism, coagulation/thrombosis, cholesterol, chronic myeloid leukemia, cardiovascular side effects",

author = "Pouwer, {Marianne G.} and Pieterman, {Elsbet J.} and Lars Verschuren and Caspers, {Martien P. M.} and Cornelis Kluft and Garcia, {Ricardo A.} and Jurjan Aman and Jukema, {J. Wouter} and Princen, {Hans M. G.}",

year = "2018",

month = jun,

day = "12",

doi = "10.3389/fcvm.2018.00055",

language = "English",

volume = "5",

journal = "Frontiers in cardiovascular medicine",

issn = "2297-055X",

publisher = "Frontiers Media S.A.",

}

Pouwer, MG, Pieterman, EJ, Verschuren, L, Caspers, MPM, Kluft, C, Garcia, RA, Aman, J, Jukema, JW & Princen, HMG 2018, 'The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model', Frontiers in cardiovascular medicine, vol. 5, 55. https://doi.org/10.3389/fcvm.2018.00055

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model. / Pouwer, Marianne G.; Pieterman, Elsbet J.; Verschuren, Lars et al.

In: Frontiers in cardiovascular medicine, Vol. 5, 55, 12.06.2018.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

AU - Pouwer, Marianne G.

AU - Pieterman, Elsbet J.

AU - Verschuren, Lars

AU - Caspers, Martien P. M.

AU - Kluft, Cornelis

AU - Garcia, Ricardo A.

AU - Aman, Jurjan

AU - Jukema, J. Wouter

AU - Princen, Hans M. G.

PY - 2018/6/12

Y1 - 2018/6/12

KW - atherosclerosis

KW - animal model cardiovascular disease

KW - lipids and lipoprotein metabolism

KW - coagulation/thrombosis

KW - cholesterol

KW - chronic myeloid leukemia

KW - cardiovascular side effects

U2 - 10.3389/fcvm.2018.00055

DO - 10.3389/fcvm.2018.00055

M3 - Article

C2 - 29946549

SN - 2297-055X

VL - 5

JO - Frontiers in cardiovascular medicine

JF - Frontiers in cardiovascular medicine

M1 - 55

ER -